Perelel has raised $27 million from Prelude Growth Partners, with participation from existing investors Unilever Ventures, Willow Growth Partners, and Selva Ventures. The company will use the funding to expand from prenatal supplements into a women’s health company serving multiple life stages.
The company has achieved profitability and doubled revenue year-over-year since its founding five years ago. Perelel currently offers products for fertility, pregnancy, postpartum, and perimenopause.
“This moment validates what we’ve built over the past five years: a business that proves women trust and return to brands that invest in clinical rigor and medically backed solutions,” said Victoria Thain Gioia, Co-Founder and CEO of Perelel. “As a women-founded firm with deep expertise in scaling consumer health and wellness brands, Prelude Growth understands both our market and our mission.”
The funding replaces early angel investors with a growth equity partner. Prelude Growth’s investment was based on Perelel’s brand positioning, products, and business metrics, including category-leading subscriber retention.
“The women’s health category is at a breaking point with influencer-led brands and unproven product claims,” said Alex Taylor, Co-Founder of Perelel. “As a doctor-founded brand with a commitment to products backed by clinical rigor and robust research, we’ve built our reputation on a foundation of trust.”
Perelel was founded by Victoria Thain Gioia, Alex Taylor, and Dr. Banafsheh Bayati. The company offers vitamin routines for preconception through perimenopause. Most Perelel products received the Clean Label Project Purity Award in 2024.
“Perelel’s doctor-founding coupled with its clinical validation and commitment to women’s health research stands out in the category,” said Neda Daneshzadeh, Co-Founder and Managing Partner of Prelude Growth. “We are extremely proud to partner with the team to support them in creating a powerhouse brand that is reimagining the future of women’s health.”
